Search Results - "Sileni, V."

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee by Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee by Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Real-world multicentre observational study of effectiveness and toxicity in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab by Faoro, L, Salizzato, V, Coppola, M, Carpanese, D, Fabozzi, A, Tondulli, L, Marconcini, R, Spagnolo, F, Del Bianco, P, Chiarion-Sileni, V, Piccin, L

Get full text

Electrochemotherapy for disseminated superficial metastases from malignant melanoma by Campana, L. G., Valpione, S., Mocellin, S., Sundararajan, R., Granziera, E., Sartore, L., Chiarion-Sileni, V., Rossi, C. R.

“…Background: The aim of the study was to determine predictive factors for effectiveness, toxicity and local disease control in patients with malignant melanoma…”
Get full text

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study by O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., Verschraegen, C., Humphrey, R., Ibrahim, R., de Pril, V., Hoos, A., Wolchok, J.D.

“…This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced…”
Get full text

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma by Maio, M., Danielli, R., Chiarion-Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., De Rosa, F., Del Vecchio, M., Di Guardo, L., Queirolo, P., Picasso, V., Marchetti, P., De Galitiis, F., Mandalà, M., Guida, M., Simeone, E., Ascierto, P.A.

“…Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced…”
Get full text

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab by Valpione, S, Martinoli, C, Fava, P, Mocellin, S, Campana, L.G, Quaglino, P, Ferrucci, P.F, Pigozzo, J, Astrua, C, Testori, A, Chiarion-Sileni, V

“…Abstract Purpose The purpose of this study was to set up a prognostic model for the identification of survival predictors specific for melanoma patients…”
Get full text

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study by Guida, M., Strippoli, S., Maule, M., Quaglino, P., Ramondetta, A., Chiaron Sileni, V., Antonini Cappellini, G., Queirolo, P., Ridolfi, L., Del Vecchio, M., Cocorocchio, E., Di Giacomo, A.M., Festino, L., Merelli, B., Occelli, M., Brugnara, S., Minisini, A., Sava, S., Tommasi, S., De Summa, S.

“…Checkpoint inhibitors in melanoma can lead to self-immune side-effects such as vitiligo-like depigmentation (VLD). Beyond the reported association with…”
Get full text

Surgery and radiotherapy in the treatment of cutaneous melanoma by Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., Eggermont, A. M. M.

“…Adequate surgical management of primary melanoma and regional lymph node metastasis, and rarely distant metastasis, is the only established curative treatment…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial by Ascierto, Paolo A, Mandalà, Mario, Ferrucci, Pier Francesso, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Fierro, Maria Teresa, Lebbè, Celeste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Gonzales Cao, Maria, Minisini, Alessandro Marco, De Placido, Sabino, Sanmamed, Miguel F, Mallardo, Domenico, Curvietto, Marcello, Melero, Ignacio, Palmieri, Giuseppe, Grimaldi, Antonio M, Giannarelli, Diana, Dummer, Reinhard, Chiarion Sileni, Vanna

“…Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for -mutant metastatic melanoma. SECOMBIT is a randomized,…”
Get full text

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy by Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M

“…Background: Retreatment with ipilimumab has been shown to re-establish disease control in some patients with disease progression. Here, we report the efficacy…”
Get full text

Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab by Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti Giancristofaro, R., Chiarion-Sileni, V., Mandruzzato, S.

“…Ipilimumab, the first immune-checkpoint inhibitor extending overall survival (OS) in metastatic melanoma patients, has a survival benefit only in a proportion…”
Get full text

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma by Long, G.V., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J.C., Kefford, R., Kirkwood, J.M., Dummer, R.

Get full text

Small molecules and targeted therapies in distant metastatic disease by Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., Schadendorf, D.

“…Chemotherapy, biological agents or combinations of both have had little impact on survival of patients with metastatic melanoma. Advances in understanding the…”
Get full text

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine by Grob, J.-J., Amonkar, M.M., Martin-Algarra, S., Demidov, L.V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller, W.H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

“…In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95%…”
Get full text

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer by De Vita, F, Orditura, M, Martinelli, E, Vecchione, L, Innocenti, R, Sileni, V C, Pinto, C, Di Maio, M, Farella, A, Troiani, T, Morgillo, F, Napolitano, V, Ancona, E, Di Martino, N, Ruol, A, Galizia, G, Del Genio, A, Ciardiello, F

“…Background: Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared with surgery alone. Methods: We…”
Get full text

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens by Chiarion-Sileni, V, Guida, M, Ridolfi, L, Romanini, A, Del Bianco, P, Pigozzo, J, Brugnara, S, Colucci, G, Ridolfi, R, De Salvo, G L

“…Background: This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated…”
Get full text

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) by Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Rutkowski, P., Cowey, C.L., Lao, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P.F., Smylie, M., Hill, A.G., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., Wolchok, J.

Get full text